https://www.selleckchem.com/products/GDC-0449.html
Prostate-specific antigen (PSA)-based detection of prostate cancer (PCa) often leads to negative biopsy results or detection of clinically insignificant PCa, more frequently in the PSA range of 2-10 ng/ml, in men with increased prostate volume and normal digital rectal examination (DRE). This study evaluated the accuracy of Proclarix, a novel blood-based diagnostic test, to help in biopsy decision-making in this challenging patient population. Ten clinical sites prospectively enrolled 457 men presenting for prostate biopsy with PSA bet
Like
Comment
Share
